Talus Bioscience

Talus Bio is a biotechnology startup dedicated to the development of gene regulation drugs. Its initial focus is on patients with high clinical needs, where transcription factors are the true drivers of tumors. Talus Bio is pioneering a new type of mass spectrometry proteomics called Data Independent Acquisition (DIA). DIA proteomics is particularly suitable for drug discovery due to its scalability, quantitative accuracy, and reproducibility.